Examkin

Question

Difficulty: MediumPreventive Care and Screening

A 48-year-old man comes to the clinic for a routine follow-up examination. Three months ago, he was diagnosed with type 2 diabetes mellitus and started on metformin. He reports that he has been adherent to his medication and has started a structured exercise program. He has no other medical conditions. He does not use tobacco or illicit drugs, and drinks alcohol occasionally. His blood pressure is 126/78 mm Hg, pulse is 76/min, and BMI is 29 kg/m2. Recent laboratory studies show a hemoglobin A1c of 6.8%. His vaccination records indicate that he received all standard childhood vaccines, a tetanus-diphtheria-acellular pertussis (Tdap) booster 3 years ago, a hepatitis B vaccine series in his twenties, and the seasonal influenza vaccine 1 month ago. He has never received a pneumococcal vaccine. Which of the following is the most appropriate recommendation regarding pneumococcal immunization for this patient?

  1. Administer a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20)Answer
  2. B
    Administer a single dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23)
  3. C
    Administer a single dose of the 13-valent pneumococcal conjugate vaccine (PCV13)
  4. D
    Administer the 20-valent pneumococcal conjugate vaccine (PCV20) now, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in 1 year
  5. E
    Defer pneumococcal vaccination until he reaches 65 years of age

Answer

Administer a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20)
The correct answer is to administer a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20). According to current Advisory Committee on Immunization Practices (ACIP) guidelines, adults aged 19 to 64 years with specific underlying medical conditions (including diabetes mellitus, chronic heart, liver, or lung disease, alcoholism, and cigarette smoking) are at increased risk for invasive pneumococcal disease. If they have not previously received a pneumococcal vaccine, they should receive either a single dose of PCV20 OR a single dose of PCV15 followed by a dose of PPSV23 at least one year later. Because this 48-year-old patient has newly diagnosed type 2 diabetes and is pneumococcal vaccine-naïve, a single dose of PCV20 is the most appropriate next step in his preventive care.

Step-by-Step Solution

1
Identify the patient's age and clinical risk factors for vaccine-preventable diseases.
The patient is a 48-year-old adult with a recent diagnosis of type 2 diabetes mellitus.
Age and specific comorbid conditions dictate the indications and timing for adult immunizations.
2
Determine the patient's previous pneumococcal vaccination history.
The patient has never received any pneumococcal vaccine.
Vaccination history determines whether an initial series or follow-up booster doses are required.
3
Apply current ACIP guidelines for pneumococcal vaccination in at-risk adults.
Adults aged 19-64 with diabetes who are pneumococcal vaccine-naïve should receive either a single dose of PCV20 or a single dose of PCV15 followed by PPSV23.
Diabetes places the patient at higher risk for invasive pneumococcal disease, necessitating early immunization with current higher-valent vaccines.

Key Concept

Adults aged 19-64 years with specific underlying medical conditions (such as diabetes mellitus) should receive either a single dose of PCV20 OR a dose of PCV15 followed by PPSV23 at least one year later.
Rate this question

Topics

Preventive Care and Screening

More questions from this topic